![Alexandra MacLean](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alexandra MacLean
Director Ejecutivo en AVENUE THERAPEUTICS, INC. .
Fortuna: - $ al 31/05/2024
Cargos activos de Alexandra MacLean
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AVENUE THERAPEUTICS, INC. | Director/Miembro de la Junta | 07/03/2023 | - |
Director Ejecutivo | 01/08/2022 | - | |
Access Vascular, Inc.
![]() Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Director/Miembro de la Junta | - | - |
Historial de carrera de Alexandra MacLean
Antiguos cargos conocidos de Alexandra MacLean.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
FORTRESS BIOTECH, INC. | Corporate Officer/Principal | 01/11/2021 | 01/07/2022 |
Imbrium Therapeutics LP
![]() Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Corporate Officer/Principal | - | - |
Formación de Alexandra MacLean.
Vagelos College of Physicians & Surgeons | Doctorate Degree |
University of Colorado Boulder | Masters Business Admin |
University of Cambridge | Graduate Degree |
McGill University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Reino Unido | 2 |
Canadá | 2 |
Operativa
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 5 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
AVENUE THERAPEUTICS, INC. | Health Technology |
FORTRESS BIOTECH, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Access Vascular, Inc.
![]() Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Health Technology |
Imbrium Therapeutics LP
![]() Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |
- Bolsa de valores
- Insiders
- Alexandra MacLean
- Experiencia